REP 2139 (REP 9AC')

REP 9AC · Replicor Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REP 2139 (REP 9AC'), covering 2016-01-05 to 2016-01-05. Get the full timeline:

Most recent: Clinical Trial Update: Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients [Phase 1, Phase 2]